Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zarnestra in Advanced Multiple Myeloma
NCT00012350Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Jan 2001
- Primary completion
- Sep 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tipifarnib in multiple myeloma (MM), sponsored by Moffitt Cancer Center. Primary endpoint: Objective Response Rate at 26 months. Started Jan 2001; status: completed.
02
Drugs
tipifarnib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00012350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00012350.